These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 22678371)

  • 41. Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy.
    Lui CY; Ju H
    Am J Cardiol; 2006 Dec; 98(11):1557-8. PubMed ID: 17126672
    [No Abstract]   [Full Text] [Related]  

  • 42. Beneficial effects of long-term enzyme replacement therapy in a child with Fabry disease.
    Martin-Suárez I; Suárez-Marrero C
    Int J Clin Pract; 2010 Jun; 64(7):995. PubMed ID: 20584233
    [No Abstract]   [Full Text] [Related]  

  • 43. Enzyme replacement therapy with agalsidase alfa in pregnant women with Fabry disease.
    Kalkum G; Macchiella D; Reinke J; Kölbl H; Beck M
    Eur J Obstet Gynecol Reprod Biol; 2009 May; 144(1):92-3. PubMed ID: 19233535
    [No Abstract]   [Full Text] [Related]  

  • 44. Fabry disease: the need to stratify patient populations to better understand the outcome of enzyme replacement therapy.
    Germain DP
    Clin Ther; 2007; 29 Suppl A():S17-8. PubMed ID: 17580237
    [No Abstract]   [Full Text] [Related]  

  • 45. [Enzyme replacement therapy in Fabry's disease].
    Alvarez L; del Pozo C; Trigueros M; Sánchez L; Albero MD; López-Menchero R; Ortega E
    Nefrologia; 2005; 25(3):322-7. PubMed ID: 16053014
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical trial for Fabry disease faces continuing hurdles.
    Silversides A
    CMAJ; 2009 Nov; 181(11):E251-2. PubMed ID: 19825933
    [No Abstract]   [Full Text] [Related]  

  • 47. Deceased renal transplantation in patient with Fabry's disease maintained by enzyme replacement therapy.
    Kato T; Nishimura K; Ichikawa Y
    Int J Urol; 2009 Jul; 16(7):650. PubMed ID: 19659805
    [No Abstract]   [Full Text] [Related]  

  • 48. Spotlight on agalsidase beta in Fabry disease.
    Keating GM; Simpson D
    BioDrugs; 2007; 21(4):269-71. PubMed ID: 17628124
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Angiokeratoma regression in a Fabry disease after treatment with agalsidase-beta: clinical effectiveness marker?
    Fauchais AL; Prey S; Ouatara B; Vidal E; Sparsa A
    J Eur Acad Dermatol Venereol; 2010 Jun; 24(6):737-8. PubMed ID: 19925601
    [No Abstract]   [Full Text] [Related]  

  • 50. Fabry disease with special reference to neurological manifestations.
    Banerjee TK
    Eur Rev Med Pharmacol Sci; 2004; 8(6):275-81. PubMed ID: 15745387
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Enzyme therapy in Fabry disease: when scarcity of one enzyme illustrates the vulnerability of biotech].
    Lidove O; Choukroun G; Bekri S; Viot G; Tsimaratos M; Joly D
    Presse Med; 2010 May; 39(5):527-9. PubMed ID: 20194001
    [No Abstract]   [Full Text] [Related]  

  • 52. [Cardiac involvement in Fabry's disease].
    Weidemann F; Breunig F
    Med Klin (Munich); 2008 Mar; 103(3):161-5. PubMed ID: 18344066
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [What is new in Fabry disease?].
    Lidove O
    Rev Med Interne; 2007 Dec; 28 Suppl 4():S296-7. PubMed ID: 17964003
    [No Abstract]   [Full Text] [Related]  

  • 54. Treatment with agalsidase beta during pregnancy in Fabry disease.
    Politei JM
    J Obstet Gynaecol Res; 2010 Apr; 36(2):428-9. PubMed ID: 20492401
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Left ventricular apical aneurysm: a novel phenotype of Fabry's disease.
    Agarwal A; Malik A; DeFranco AC; Tajik AJ
    Eur Heart J Cardiovasc Imaging; 2014 May; 15(5):585. PubMed ID: 24196119
    [No Abstract]   [Full Text] [Related]  

  • 56. Avascular necrosis of bilateral femoral heads in a patient with Fabry's disease.
    O'Neill F; Rice J
    Hip Int; 2012; 22(1):119-21. PubMed ID: 22383317
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The fate of internalized alpha-2-macroglobulin: alpha-galactosidase conjugate in fibroblasts from Fabry's hemizygote.
    Osada T; Kuroda Y; Ikai A
    Biochem Biophys Res Commun; 1987 Mar; 143(3):954-8. PubMed ID: 2436620
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Assessing antibodies to alpha-galactosidase A in Fabry disease.
    Richards SM
    Clin Ther; 2007; 29 Suppl A():S7-8. PubMed ID: 17580240
    [No Abstract]   [Full Text] [Related]  

  • 59. Pediatrics: implementing the promise of early intervention for Fabry disease.
    Raas-Rothschild A
    Clin Ther; 2007; 29 Suppl A():S6. PubMed ID: 17580239
    [No Abstract]   [Full Text] [Related]  

  • 60. Fabry disease in an oligosymptomatic male.
    Altarescu G; Elstein D
    Isr Med Assoc J; 2011 Mar; 13(3):191-2. PubMed ID: 21608346
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.